Langues

24 June 2015 - Rett Syndrome Research Trust awards a new research grant to Neurolixis

Neurolixis Inc. has been awarded a new research grant by the Rett Syndrome Research Trust (RSRT) to advance development of NLX-101, a promising clinical-phase candidate for treatment of Rett syndrome. The grant is the second that Neurolixis has received from the RSRT and will support Chemistry, Manufacturing, and Controls (CMC) studies, preparation of clinical protocols and filing an Investigational New Drug (IND) application for a clinical trial in Rett syndrome patients.

Rett syndrome is a rare and devastating neurological disorder which affects 1 in 10,000 females and for which there is no approved treatment. NLX-101 has shown marked activity in transgenic mouse models of Rett syndrome and has been awarded Orphan Drug designation for this indication in both the USA and in the European Union.

Read the full Neurolixis press release:  pdf_symbol

Read the Rett Syndrome Research Trust announcement.

Pipeline prometteur

Neurolixis a acquis les droits de développement exclusifs mondiaux pour deux composés en développement clinique (Phase 1 et Phase 2). Ils ciblent des indications neurologiques et psychiatriques où il existe de forts besoins médicaux. Lire la suite...

Recherche

Neurolixis a reçu plusieurs financements de la part de fondations de recherche, y compris Parkinson's UK, la Michael J. Fox Foundation, la Rett Syndrome Research Trust, l'International Rett Syndrome Foundation et la Région Occitanie.    Lire la suite...

Domaine thérapeutique

Neurolixis développe des composés en phase clinique pour le traitement des dyskinésies chez les patients atteints de la maladie de Parkinson, et pour les troubles respiratoires chez les patients atteints par le syndrome de Rett, une maladie génétique orpheline. Lire la suite...